Cambrian Biopharma � CAM-7520

Cambrian Biopharma is a biotechnology company focused on developing treatments that target the underlying biology of aging to extend human healthspan. They aim to create a pipeline of therapeutics addressing the various hallmarks of aging and age-related diseases. By targeting these hallmarks, Cambrian Biopharma seeks to develop therapies that can potentially delay, prevent, or treat multiple age-related diseases simultaneously. The company’s strategy involves acquiring, licensing, and investing in early-stage biotechnology companies and assets that target the fundamental biology of aging. They support these assets through their development, preclinical, and clinical phases to create innovative treatments for age-related diseases.Cambrian Biopharma was founded in 2021 by James Peyer. In conjuction with Oviva, Cambria intends to develop CAM-7520 to address changes in endocrine signaling by targeting the AMH/AMR2 axis. Targeting the AMH/AMR2 axis as intended is expected to extend ovarian function and improve female healthspan.